GlobeImmune resumes Louisville manufacturing

LOUISVILLE — After selling to California-based NantCell Inc., GlobeImmune is restarting operations at its Louisville facility.

GlobeImmune’s Lousiville facility (Photo courtesy GlobeImmune website.)

The company will be manufacturing at its Louisville facility to support clinical trials for products targeting certain cancers and tumors.

NantCell purchased a controlling interest of GlobeImmune in March for more than $2 million.